Syndax Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapies. Its lead products include SNDX-5613 for KMT2Ar and NPM1 acute myeloid leukemia, and SNDX-6352 for chronic graft versus host disease. The company is also developing Entinostat and has a licensing agreement with Eddingpharm International. Syndax Pharmaceuticals was founded in 2005 and is based in Waltham, Massachusetts.